Menu
Search Clinical Trials
Back to Search Results
Terminated
Astellas Study ID
8273-CL-0202

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

Astellas Study ID
NCT02500927
Clinicaltrials.gov ID
NCT02500927
EUCTIS ID
N/A
EudraCT ID
N/A
jRCT ID
N/A
CN CDE ID
N/A
Get more information

Study summary

The purpose of this study is to determine the safety, the antitumor activity and the pharmacokinetics of ASP8273 in EGFR tyrosine kinase inhibitor (EGFR-TKI)-naïve patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.

Additional Study Details

Phase
2
Product
  • ASP8273 Capsules
  • ASP8273 Capsules A
    • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    31
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Download Document(s)
    Plain Language Summary
    Available Language(s): Japanese
    Download Document(s)

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Republic of Moldova
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Former Serbia and Montenegro
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Republic of Korea
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site: 7
      Kanagawa, Japan
      Contact Us
      Completed
      Site: 1
      Miyagi, Japan
      Contact Us
      Terminated
      Site: 3
      Osaka, Japan
      Contact Us
      Completed
      Site: 2
      Tokyo, Japan
      Contact Us
      Terminated
      Site: 4
      Okayama, Japan
      Contact Us
      Terminated
      Site: 11
      Miyagi, Japan
      Contact Us
      Completed
      Site: 8
      Hyogo, Japan
      Contact Us
      Terminated
      Site: 5
      Fukuoka, Japan
      Contact Us
      Terminated
      Site: 10
      Nagoya, Japan
      Contact Us
      Terminated
      Site: 9
      Hiroshima, Japan
      Contact Us
      Terminated
      Site: 6
      Osaka, Japan
      Contact Us
      Trial info
      Follow Trial
      Age
      20+ years
      Diamond icon
      Condition
    • Non Small Cell Lung Cancer
      • Gender icon
      Sex
      Female & Male
      Calendar icon
      Trial Dates
      Jun 2015 - Jun 2017
      Additional Study Details
      Inclusion Criteria
      • Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
      • Patients with a histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC.
      • Patients confirmed to have the deletion of exon 19 (del ex19), L858R, G719X, or L861Q mutation among the EGFR activating mutations (patients at the study site who are documented to have any of the above-stated EGFR activating mutations can be enrolled in the study).
      • Patients with a life expectancy ≥ 12 weeks based on the principal investigator’s/subinvestigator’s judgment.
      • Patients who meet all of the following requirements for laboratory tests within 7 days before enrollment. When 2 or more test results for a single parameter are found within the specified period, the last data before enrollment should be used for assessment.
        • Neutrophil count: ≥ 1,500/mm3
        • Platelet count: ≥ 75,000/mm3
        • Hemoglobin: ≥ 9 g/dL
        • Serum creatinine: < 1.5 mg/dL
        • Total bilirubin (TBL): < 1.5 × the upper limit of normal (ULN) at the site (this does not apply to patients with Gilbert syndrome)
        • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): < 2.5 ×the ULN at the site
      • Patients who meet all the following requirements for prior treatment for NSCLC:
        • Patients who have not received previous treatment with EGFR-TKIs*1
      • *1: Erlotinib, gefitinib, afatinib, and EGFR-TKIs under clinical investigation (e.g.,neratinib, dacomitinib). EGFR-TKIs that can inhibit EGFR with the T790Mmutation (e.g., ASP8273, CO-1686, AZD9291) are also included.
      • Patients who have not received more than one regimen of previous drug treatment (however, this does not include preoperative or postoperative therapies used within at least a 6-month interval after the last dose of the treatment).
      • Patients who have at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
      MaximizeExclusion Criteria
      • Patients with persistent clinical evidence of previous antitumor treatment-related toxicity ≥ Grade 2 using the Japan Clinical Oncology Group (JCOG) Japanese translation of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (NCI CTCAE v4.0 – JCOG) (except alopecia).
      • Patients with a history of or concurrent interstitial lung disease.
      • Patients who have received previous treatment with intended antitumor effects or treatment with another investigational drug/medical device within 14 days before the start of the study treatment.
      • Patients who have received transfusion or hematopoietic growth factor therapy within 14 days prior to the start of the study treatment.
      • Patients who have received oral or intravenous corticosteroids within 7 days prior to the start of the study treatment (except to treat or prevent an allergic reaction).
      • Patients who are scheduled to undergo a surgical procedure during the course of the study or the patient still has an unhealed wound after previous surgery.
      • Patients with a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (anti-HCV).
      • Patients with a known history of a positive test for human immunodeficiency virus (HIV) infection.
      • Patients with symptomatic central nervous system (CNS) lesions.
      • Patients with a known history of serious drug hypersensitivity.
      • Patients with evidence of active infection requiring systemic drug therapy within 14 days prior to the start of the study treatment.
      • Patients who have received strong CYP3A inhibitors within 9 days prior to the start of the study treatment (for itraconazole, within 14 days prior to the start of the study treatment).
      • Patients who have received moderate CYP3A inhibitors within 9 days prior to the start of the study treatment (only for subjects included in BA evaluation).
      • Patients who have received strong or moderate CYP3A inducers within 14 days prior to the start of the study treatment (only for subjects included in BA evaluation).
      • Patients with prolongation of the QTc interval (male: ≥ 451 ms, female: ≥ 471 ms) on the 12-lead electrocardiogram (ECG) in the screening period.
      • Patients with cardiac arrhythmias requiring treatment.
      • Patients with Class 3 or 4 New York Heart Association (NYHA) congestive heart failure.
      • Patients with a history of acute coronary syndrome, myocardial infarction, or cerebrovascular accident within 6 months prior to enrollment.
      • Patients with a history of or concurrent active peptic ulcer disease or gastrointestinal bleeding within 3 months prior to enrollment.
      • Patients with corneal disease ≥ Grade 2.
      • Patients with difficulty to take oral medication, or any gastrointestinal malfunction or inflammatory bowel disease that is considered to affect drug absorption.
      • Patients with active multiple cancers (simultaneous multiple cancers).
      • Patients with other conditions ineligible for participation in the study based on the principal investigator’s/sub-investigator’s judgment.

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      Find a Trial
      2

      Why are Clinical Trials Important?

      Learn More
      3

      Why Participate in a Clinical Trial?

      Discover More

      For Your Information

      THE PURPOSE OF THIS WEBSITE IS TO OFFER EDUCATION AND INFORMATION TO PATIENTS AND THEIR FAMILIES AND FRIENDS, THE PUBLIC, AND HEALTHCARE PROFESSIONALS ABOUT THE CLINICAL TRIAL PROCESS. IN ADDITION, THE WEBSITE WILL PROVIDE SPECIFIC INFORMATION ABOUT ASTELLAS CLINICAL TRIALS. PLEASE READ THE COMPLETE ASTELLAS TRANSPARENCY POLICY TO LEARN ABOUT THE CLINICAL TRIAL INFORMATION AVAILABLE ON THIS WEBSITE